| Literature DB >> 36006149 |
Jurgen Buekers1, Sylvie Remy1, Jos Bessems1, Eva Govarts1, Loïc Rambaud2, Margaux Riou2, Janja Snoj Tratnik3, Anja Stajnko3, Andromachi Katsonouri4, Konstantinos C Makris5, Annelies De Decker6, Bert Morrens7, Nina Vogel8, Marike Kolossa-Gehring8, Marta Esteban-López9, Argelia Castaño9, Helle Raun Andersen10, Greet Schoeters1,11.
Abstract
Few data are available on the exposure of children to glyphosate (Gly) in Europe. Within HBM4EU, new HBM exposure data were collected from aligned studies at five sampling sites distributed over Europe (studies: SLO CRP (SI); ORGANIKO (CY); GerES V-sub (DE); 3XG (BE); ESTEBAN (FR)). Median Gly concentrations in urine were below or around the detection limit (0.1 µg/L). The 95th percentiles ranged between 0.18 and 1.03 µg Gly/L. The ratio of AMPA (aminomethylphosphonic acid; main metabolite of Gly) to Gly at molar basis was on average 2.2 and the ratio decreased with higher Gly concentrations, suggesting that other sources of AMPA, independent of metabolism of Gly to AMPA in the monitored participants, may concurrently operate. Using reverse dosimetry and HBM exposure data from five European countries (east, west and south Europe) combined with the proposed ADI (acceptable daily intake) of EFSA for Gly of 0.1 mg/kg bw/day (based on histopathological findings in the salivary gland of rats) indicated no human health risks for Gly in the studied populations at the moment. However, the absence of a group ADI for Gly+AMPA and ongoing discussions on e.g., endocrine disrupting effects cast some uncertainty in relation to the current single substance ADI for Gly. The carcinogenic effects of Gly are still debated in the scientific community. These outcomes would influence the risk conclusions presented here. Finally, regression analyses did not find clear associations between urinary exposure biomarkers and analyzed potential exposure determinants. More information from questionnaires targeting exposure-related behavior just before the sampling is needed.Entities:
Keywords: AMPA; HBM; HBM4EU; children; exposure; glyphosate
Year: 2022 PMID: 36006149 PMCID: PMC9415901 DOI: 10.3390/toxics10080470
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
Urinary Gly concentrations in European children (6–11 yrs.) from HBM4EU-aligned studies.
| Study | Sampling Year | N | Age Range (yrs.) | Sex (F/M) | Urine Sample | Method | LOD Gly (µg/L) | LOQ Gly (µg/L) | % < LOQ f | Gly (µg/L) | Creatinine-Adjusted Gly (µg/g crt) g | CreatinineMedian (P5 and P95) in mg/dL | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P25 | P50 | P75 | P95 | P25 | P50 | P75 | P95 | |||||||||||
| SLO CRP children (Slovenia) a | 2018 | 149 | 7–10 | (82/67) | Morning (140) and spot (9) | GC/MS-MS | 0.1 | 76 | <LOQ | <LOQ | <LOQ | 0.18 | 0.19 | 102 (42–175) | ||||
| ORGANIKO (Cyprus) b | 2017 | 166 | 10–11 | (80/86) | Morning | GC/MS-MS | 0.03 | 0.1 | 55 | <LOQ | <LOQ | 0.18 | 1.03 | 0.15 | 0.76 | 108 (53–205) | ||
| GerES V-sub d (Germany) a | 2015–2017 | 300 | 6–12 c | (150/150) | Morning (296) and spot (4) | GC/MS-MS | 0.1 | 47 | <LOQ | 0.10 = LOQ | 0.17 | 0.43 | 0.07 | 0.15 | 0.37 | 110 (49–204) | ||
| 3XG (Belgium) b | 2019–2020 | 133 | 6–8 | (67/66) | Morning (110) and spot (23) | LC/MS-MS | 0.1 | 40 | <LOQ | 0.12 | 0.22 | 0.41 | 0.11 | 0.21 | 0.58 | 97 (33–166) | ||
| ESTEBAN (France) a | 2014–2016 | 223 | 6–11 | (115/108) | Morning | LC/MS-MS | 0.02 | 0.05 | 83 | <LOQ | <LOQ | <LOQ | 0.65 | 0.84 | 87 (32–164) | |||
| Combined data e | 748 | 6–12 | (494/477) | 0.15 | 0.48 | 0.13 | 0.51 | |||||||||||
a: Biomarker data generated before HBM4EU QA/QC program and comparability cannot be guaranteed (see Esteban López et al., 2021) [17]; b: Biomarker data quality assured by HBM4EU QA/QC program; c: GerES V-sub included 19 children who have turned 12 between the first examination and urine collection date. d: GerES V-sub is an unweighted subset of 300 children of the nationally representative GerES V; e: Results of all datasets combined regardless of result QA/QC program; f: Each study was compared to its own LOQ. Data represent the percentage of participants having a value lower than the LOQ; g: Values < LOQ set to LOQ/2.
Summary of urinary AMPA concentrations in European children (6–11 yrs.) from the HBM4EU-aligned studies.
| Study | LOD | LOQ | % < LOQ | AMPA (µg/L) | Creatinine-Adjusted AMPA (µg/g crt) c | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| P25 | P50 | P75 | P95 | P25 | P50 | P75 | P95 | ||||
| SLO CRP children a | 0.1 | 53 | <LOQ | <LOQ | 0.14 | 0.29 | 0.13 | 0.26 | |||
| ORGANIKO b | 0.03 | 0.1 | 25 | =LOQ | 0.17 | 0.28 | 0.66 | 0.05 | 0.15 | 0.23 | 0.57 |
| GerES V-sub a | 0.1 | 53 | <LOQ | <LOQ | 0.21 | 0.48 | 0.17 | 0.40 | |||
| 3XG b | 0.2 | 74 | <LOQ | <LOQ | 0.20 | 0.40 | 0.14 | 0.37 | |||
| ESTEBAN a | 0.02 | 0.05 | 4 | 0.11 | 0.18 | 0.24 | 0.43 | 0.12 | 0.19 | 0.30 | 0.59 |
| Combined data | 0.22 | 0.47 | 0.21 | 0.45 | |||||||
a: Biomarker data generated before HBM4EU QA/QC program but deemed comparable (see Esteban López et al., 2021) [17]; b: Biomarker data quality assured by HBM4EU QA/QC program; c: Values
Urinary Gly and AMPA concentrations in children reported in other European studies.
| Study | Country | Sampling Year | Population | Urine Sample | Method (Instrumentation) | Gly, µg/L | AMPA, µg/L | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| LOQ/LOQ | Average | P95 | LOD/LOQ | Average | P95 | ||||||
| Ferreira et al. 2021 [ | Portugal | 2018–2019 | 41 children 2–13 y | Spot | ELISA | LOD = 0.6 | AM = 1.77 | ||||
| Knudsen et al. 2017 [ | Denmark | 2011 | 14 children 6–11 y | Spot | ELISA | LOD = 0.08 | AM = 1.96 | ||||
| Lemke et al. 2021 [ | Germany | 2015–2017 | 2144 children and adolescents 3–17 y | First morning | GC/MS-MS | LOQ = 0.1 | AM = 0.16 | 0.51 | LOQ = 0.1 | AM = 0.16 | 0.48 |
| Stajnko et al. 2020 [ | Slovenia | 2018 | 246 children and adolescents 7–10 y and 12–15 y | First morning (January–March) | GC/MS-MS | LOQ = 0.1 | GM < LOQ | 0.19 | LOQ = 0.1 | GM < LOQ | 0.29 |
| 225 children and adolescents 7–10 y and 12–15 y | Fist morning (May–June) | GC/MS-MS | LOQ = 0.1 | GM < LOQ | 0.19 | LOQ = 0.1 | GM = 0.1 | 0.33 | |||
LOD: limit of detection; LOQ: limit of quantification; AM: arithmetic mean; GM: geometric mean; P95: 95th percentile. a: results of publication Lemke et al. (2021) [26] include all participants of GerES V (i.e., children + adolescents); b: results of publication Stajnko et al. (2020) [27] include children and adolescents.
Figure 1Pooled HBM4EU-aligned study data from five European countries (Belgium, Cyprus, Germany, Slovenia, France) for Gly and AMPA in children. Data are expressed on a natural logarithmic scale: panel (a) Creatinine-corrected concentrations (µmol/g creatinine); panel (b) Volume-based concentrations (µmol/L). The 1:1 line (full line) is indicated. Values below LOQ were excluded.
Risk assessment of glyphosate based on HBM data (detection of Gly and AMPA with mass spectrometry).
| Ref. | Country | P95 Concentration Glyphosate | PDI | PDI | PDI/ADI |
|---|---|---|---|---|---|
| µg/L | µg/day | µg/kg bw/day | % | ||
| SLO CRP children (HBM4EU) | Slovenia | 0.18 | =0.18 × 0.7/0.57% = 22 | =22/30 = 0.74 | =0.00074/0.1 = 0.74% |
| ORGANIKO (HBM4EU) | Cyprus | 1.03 | 126 | 4.22 | 4.22% |
| GerES V-sub (HBM4EU) | Germany | 0.43 | 53 | 1.76 | 1.76% |
| 3XG (HBM4EU) | Belgium | 0.41 | 50 | 1.68 | 1.68% |
| ESTEBAN (HBM4EU) | France | 0.65 | 80 | 2.66 | 2.66% |
| Lemke et al. 2021 [ | Germany | 0.51 | 63 | 2.09 | 2.09% |
| Stajnko et al. 2020 [ | Slovenia | 0.19 | 23 | 0.78 | 0.78% |
PDI: predicted daily intake; ADI: acceptable daily intake; P95: 95th percentile. Assumed bodyweight set at 30 kg, urinary volume at 0.7 L/day and FUE at 0.57%. ADI was set at 0.1 mg/kg bw/day.
Logistic backward multiple regression for glyphosate and AMPA based on individual studies from HBM4EU.
| Study | Variable | OR = Exp(β) | 95%CI | ||
|---|---|---|---|---|---|
| Glyphosate | Slovenia | Intercept | 0.15 | ||
| Creatinine | 1.01 | (1.00;1.02) | 0.041 | ||
| Matrix | 1.08 | (0.19;5.96) | 0.933 | ||
| BMI | 0.98 | (0.87;1.10) | 0.698 | ||
| Use of pesticide outdoor (No: 76; Yes: 73) | 2.37 | (1.07;5.25) |
| ||
| Model |
| ||||
| Belgium | Intercept | 0 | |||
| Creatinine | 1.02 | (1.01;1.03) | 0.001 | ||
| Matrix | 1.08 | (0.38;3.07) | 0.890 | ||
| BMI | 1.03 | (0.84;1.26) | 0.782 | ||
| Age (6–8 y) | 2.61 | (1.12;6.06) |
| ||
| Pets in home (No: 80; Yes: 53) | 2.73 | (1.20;6.21) |
| ||
| Model |
|
OR: odds ratio. BMI, creatinine (crt) and matrix (spot urine; first-morning urine) were forced into the model. Only multiple regression models with p less than or close to 0.05 shown.